ReviewPyoderma gangrenosum: A review and update on new therapies
Section snippets
Local wound management
Effective management of PG ulcers is an objective evaluation of the ulcers so that wound management can be planned. At each visit, objective measurements including depth, length, and width of the ulcer should be recorded.6 These measurements in combination with sequential photography can then serve as a gauge for wound management success. The inflammatory component of PG is assessed by the border elevation and lesion expansion. When the border flattens, anti-inflammatory medications can be
Pain control
With the exception of the vegetative variant, patients with PG almost universally experience debilitating pain, sometimes described as “stabbing” in quality. The pain can become so severe that amputation has been implemented when systemic therapy is ineffective.7 Although patients with the vegetative variant of PG may have some tenderness, the pain is generally less than that experienced by patients with other types of PG. The source of the pain is multifactorial, but much of it can be
Treatments
There is currently no gold standard of treatment for PG.9 Choice of therapy will depend on multiple factors including size and depth of the lesion, the rapidity of lesion growth and appearance of new lesions, the associated disease (eg, inflammatory bowel disease, arthritis), and general medical status of the patient. Other factors in choice of treatment include associated toxicities of the medications, as up to 50% of patients with classic PG require long-term therapy to maintain remission.9
Clinical trials
Several studies have emerged showing the benefit of using biologics (infliximab, etanercept, efalizumab, adalimumab, and alefacept) for the treatment of PG. Most of the studies used an end point of complete resolution of lesions (Table III). However, this is not the most sensitive method for detecting efficacy, as many biologics may yield significant clinical improvement without complete resolution of lesions or lesions may require more time for complete healing than the constraints of the
References (63)
- et al.
Pyoderma gangrenosum: classification and management
J Am Acad Dermatol
(1996) - et al.
Management of peristomal pyoderma gangrenosum
J Am Coll Surg
(2008) - et al.
Treating the chronic wound: a practical approach to the care of nonhealing wounds and wound care dressings
J Am Acad Dermatol
(2008) Non-melanoma skin cancer: importance of gender, immunosuppressive status and vitamin D
Cancer Lett
(2008)- et al.
The treatment of pyoderma gangrenosum using etanercept
J Am Acad Dermatol
(2006) - et al.
Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease
Am J Gastroenterol
(2003) - et al.
Treatment of pyoderma gangrenosum
J Am Acad Dermatol
(1996) - et al.
Pyoderma gangrenosum: a comparison of typical and atypical forms with an emphasis on time to remission; case review of 86 patients from 2 institutions
Medicine (Baltimore)
(2000) - et al.
Andrews' diseases of the skin: clinical dermatology
(2000) - et al.
Treatment of pyoderma gangrenosum with intravenous immunoglobulin
Br J Dermatol
(2007)
Pyoderma gangrenosum–a review
Orphanet J Rare Dis
Pyoderma gangrenosum: a case study for pain management in dermatology nursing
Dermatol Nurs
Pyoderma gangrenosum: a report of 44 cases with follow-up
Br J Dermatol
Topical tacrolimus for pyoderma gangrenosum: another report
J Dermatol
Successful treatment of severe pyoderma gangrenosum with pimecrolimus cream 1%
J Eur Acad Dermatol Venereol
Efficacy and systemic absorption of topical tacrolimus used in pyoderma gangrenosum
Br J Dermatol
Systemic absorption of topical tacrolimus in pyoderma gangrenosum
Acta Derm Venereol
Topical treatment of pyoderma gangrenosum
Dermatology
Topical treatment with 1% sodium cromoglycate in pyoderma gangrenosum
Dermatology
Topical disodium cromoglycate in the management of pyoderma gangrenosum
Cutis
Successful treatment of pyoderma gangrenosum with topical 5-aminosalicylic acid
Cutis
Pyoderma gangrenosum–response to topical nitrogen mustard
Clin Exp Dermatol
Infliximab for the treatment of pyoderma gangrenosum: a randomized, double blind, placebo controlled trial
Gut
Off-label uses of biologic agents in dermatology: a 2006 update
Semin Cutan Med Surg
Pyoderma gangrenosum treated with anti-TNF alpha therapy (etanercept)
Clin Exp Dermatol
Treatment of pyoderma gangrenosum with etanercept
J Drugs Dermatol
Use of etanercept in treatment of pyoderma gangrenosum in a patient with autoimmune hepatitis
J Dermatolog Treat
Etanercept for the treatment of refractory pyoderma gangrenosum: a brief series
Int J Dermatol
Pyoderma gangrenosum–rebel without a cure?
Int J Dermatol
Adalimumab for treatment of pyoderma gangrenosum
Br J Dermatol
Adalimumab therapy for recalcitrant pyoderma gangrenosum
J Burns Wounds
Cited by (195)
Dermatological manifestations of hematologic neoplasms. Part II: nonspecific skin lesions/paraneoplastic diseases
2023, Anais Brasileiros de DermatologiaPyoderma gangrenosum after COVID-19 infection and vaccination
2023, Clinics in DermatologyThe Pathophysiology and Treatment of Pyoderma Gangrenosum—Current Options and New Perspectives
2024, International Journal of Molecular SciencesCURRENT AND EMERGING TRENDS IN THE MANAGEMENT OF PYODERMA GANGRENOSUM: A LITERATURE REVIEW
2023, Journal of Ayub Medical CollegeClinical guidance of pyoderma gangrenosum 2022
2023, Journal of DermatologyPyoderma gangrenosum
2023, BMJ
Astellas Pharma Global Development Inc provided support for the preparation of this review. The Center for Dermatology Research is supported by an unrestricted educational grant from Galderma Laboratories LP.
Disclosure: Dr Feldman has received research, speaking, and/or consulting support from Abbott Labs, American Society for Dermatologic Surgery, Amgen, Astellas, Aventis Pharmaceuticals, Biogen, Centocor, Connetics, Galderma, Genentech, Novartis, and Roche. Dr Jorizzo has received speaking and/or consulting support from Amgen. Dr Miller, Dr Yentzer, and Ms Clark have no conflicts of interest to declare.
Reprints not available from the authors.